Shark Tank India judge, Namita Thapar, is set to reap substantial returns following her decision to partially divest her stake in Emcure Pharmaceuticals Ltd., where she is an executive director.
Thapar stands to achieve a 293-fold return on her initial investment at the upper end of the price band set for the company’s initial public offering, according to the red herring prospectus.
The IPO, which opens on July 3, comprises a fresh issue worth Rs 800 crore and an offer for sale of 1.14 crore equity shares from shareholders and promoters.
Thapar, holding 63,39,800 shares amounting to a 3.5% stake in Emcure, will sell 12,68,600 shares through offer for sale.
Her average cost of acquisition per share stands at Rs 3.44, resulting in a total initial investment of Rs 2.18 crore.
Shark Tank India judge, Namita Thapar, is set to reap substantial returns following her decision to partially divest her stake in Emcure Pharmaceuticals Ltd., where she is an executive director. Thapar stands to achieve a 293-fold return on her initial investment at the upper end of the price band set for the company’s initial public offering, according to the red herring prospectus.
The IPO, which opens on July 3, comprises a fresh issue worth Rs 800 crore and an offer for sale of 1.14 crore equity shares from shareholders and promoters. The price band has been fixed at Rs 960 to Rs 1,008 per share.
Thapar, holding 63,39,800 shares amounting to a 3.5% stake in Emcure, will sell 12,68,600 shares through offer for sale. Her average cost of acquisition per share stands at Rs 3.44, resulting in a total initial investment of Rs 2.18 crore.
